To investigate whether CBL mutations we identified previously affect the protein expression regulation of both EGFR and MET in NSCLC, we first used anti-CBL shRNA to silence CBL in A549 cells that had very low CBL endogenous protein expression. This evidence concerns the gene CBL and non-small cell lung carcinoma.